Post-earnings recap
Reported
Mon, May 11, 2026
EPS actual
$0.52
EPS est.
$0.34
EPS surprise
+54.76%
1-day move
+25.60%
Liquidia Corporation reported better-than-expected earnings per share, which is a positive indicator for the company's profitability. However, the stock saw a slight decline of 0.02%, suggesting that investors may have been expecting more clarity or additional information that was not provided in this report. The lack of revenue figures and guidance may have contributed to the muted stock reaction.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $0.52 | $0.41 | +54.76% |
| Revenue | — | $117M | — |
No transcript is on record, and the analysis is based solely on numerical results.
Liquidia Corporation is a pharmaceutical company focused on developing innovative treatments for patients with serious diseases. With a market cap of $4 billion, it operates in the health care sector, addressing significant medical needs through its proprietary technologies.
Last quarter
In the last quarter, Liquidia reported an EPS of $0.15, significantly beating estimates of $0.07. The stock reacted positively, gaining 0.41% the following day.
EPS beat streak
4Q
EPS beat rate
63%
Avg EPS surprise
+30.33%
Avg 1-day reaction
+3.09%
Analysts are cautiously optimistic about Liquidia's upcoming earnings, expecting a solid EPS and revenue performance. The company has shown a capacity for surprising the market positively in recent quarters.
Bull case
If Liquidia meets or exceeds the consensus estimates, it could signal strong demand for its products and effective cost management, leading to a positive stock reaction.
Bear case
Conversely, if the company fails to meet expectations, it may raise concerns about its growth prospects and market position, potentially leading to a negative stock reaction.
Key metrics to watch
EPS
$0.41Earnings per share is a key indicator of profitability and will show how well the company is managing costs and generating income.
Revenue
$117MRevenue figures will provide insight into the company's sales performance and market demand for its products.
The print will turn on these.
Q1
Will Liquidia's EPS exceed the consensus estimate of $0.41?
A beat on EPS could reinforce investor confidence and drive the stock price up, while a miss could lead to negative sentiment.
Q2
What is the revenue figure compared to the expected $117 million?
Revenue performance is critical for assessing the company's market demand and growth trajectory, impacting future forecasts.
—
Est. EPS
$0.11
Est. Rev
$714M
Impl. Move
±15.7%
Why consensus could be wrong
The consensus may underestimate Liquidia's ability to capitalize on recent product developments, which could lead to higher-than-expected revenue.
Supporting evidence
Liquidia has a history of surprising the market positively, as seen in recent quarters.
The options market is pricing in a larger move than historical averages suggest, indicating potential for a significant reaction.
Key risk
If revenue comes in below $97 million, it could undermine the optimistic projections for the company's growth.
Pre-commit to what would confirm each case.
The market is debating Liquidia's ability to sustain profitability and revenue growth in a competitive pharmaceutical landscape.
Bull confirmed if
Earnings per share of $0.41 or higher would confirm the bullish outlook.
Bear confirmed if
Earnings per share below $0.33 would support the bearish case.
What the market is pricing for the move.
Implied Move
±14.35%
Historical Avg
±7.7%
The options market is pricing in a significant move, indicating that traders expect volatility around the earnings report.
Options are pricing ±14.4% while LQDA has averaged ±7.7% over the last 8 prints — setup is pricing rich.
ATM IV
1.3%
30d HV
46.1%
Open-market trades by officers, directors, and 10%+ holders over the trailing 90 days.
Bought
$0.00
0 sh
0 insiders
Sold
$6.4M
235,477 sh
1 insider
Net
$6.4M
Net selling
Most Active Insiders· 1 open-market trade
Smart-money positioning from the most recent 13F filings.
Institutional
81.95%
of float
Insider
9.24%
of float
Holders
435
institutions
Top Holders· as of Jun 2026
Blackrock Inc.
10,788,586 sh · $287.8M
12.05%
96.5%
Likely market behavior by outcome. Not investment advice.
Beat & raise
If Liquidia beats expectations, history suggests a positive stock reaction, potentially gaining around +0.18% on the first day.
In line / cautious
If results are in line with expectations, the stock may experience muted movement as investors await further guidance.
Miss
A miss could lead to a decline, with history indicating an average drop of around +2.68% on such outcomes.
The lines on the call that would change the story.
$6.4M
Net selling
Recent Transactions
Oct 5, 2026 · @ $27.13
235,477 sh
$6.4M
Open-market trades only (Form 4 codes P/S). Awards, exercises, and tax-withholding excluded as routine compensation noise.
Farallon Capital Management LLC
8,365,038 sh · $223.2M
9.35%
-3.4%
Caligan Partners, LP
8,118,892 sh · $216.6M
9.07%
Flat
Findell Capital Management LLC
3,502,112 sh · $93.4M
3.91%
Flat
Vanguard Capital Management LLC
3,139,183 sh · $83.8M
3.51%
7.2%
13F filings updated quarterly. Position deltas show change in shares vs. the prior quarter.